[
    [
        {
            "time": "2021-06-19",
            "original_text": "医药龙头药明康德股东偷偷减持29亿 证监会最新发声：依法处理！ 减持股份",
            "features": {
                "keywords": [
                    "药明康德",
                    "股东减持",
                    "证监会",
                    "依法处理"
                ],
                "sentiment_score": -0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "医药龙头药明康德股东偷偷减持29亿 证监会最新发声：依法处理！ 减持股份",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 10,
                "Source_Recency": 10
            }
        },
        {
            "time": "2021-06-19",
            "original_text": "证券市场禁入新规下月实施 资本市场违法违规零容忍",
            "features": {
                "keywords": [
                    "证券市场",
                    "禁入新规",
                    "资本市场",
                    "违法违规"
                ],
                "sentiment_score": -0.5,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "证券市场禁入新规下月实施 资本市场违法违规零容忍",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 6,
                "Duration": 9,
                "Entity_Density": 4,
                "Market_Scope": 10,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-06-19",
            "original_text": "医药行业周报：国内首个CAR-T即将获批 如何看CGT领域未来？",
            "features": {
                "keywords": [
                    "医药行业",
                    "CAR-T",
                    "CGT领域",
                    "获批"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药行业周报：国内首个CAR-T即将获批 如何看CGT领域未来？",
                "Correlation": 6,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-06-19",
            "original_text": "细胞疗法新秀Lyllel登录纳斯达克：市值超39亿美元，高瓴、红杉、药明康德为股东",
            "features": {
                "keywords": [
                    "细胞疗法",
                    "Lyllel",
                    "纳斯达克",
                    "药明康德"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "细胞疗法新秀Lyllel登录纳斯达克：市值超39亿美元，高瓴、红杉、药明康德为股东",
                "Correlation": 7,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-06-19",
            "original_text": "证监会问答，涉ST中安、康得新、药明康德等",
            "features": {
                "keywords": [
                    "证监会",
                    "ST中安",
                    "康得新",
                    "药明康德"
                ],
                "sentiment_score": -0.4,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "证监会问答，涉ST中安、康得新、药明康德等",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-06-19",
            "original_text": "“偷偷”减持29亿惹众怒 药明康德这位股东什么来头？记者探访注册地 减持股份",
            "features": {
                "keywords": [
                    "药明康德",
                    "股东减持",
                    "偷偷",
                    "注册地"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "“偷偷”减持29亿惹众怒 药明康德这位股东什么来头？记者探访注册地 减持股份",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 10,
                "Source_Recency": 10
            }
        },
        {
            "time": "2021-06-19",
            "original_text": "17个药品被禁用，招采违规遭严打，知名药企掀裁员潮，科伦、齐鲁...27个注射剂集采中标 其他违规处罚",
            "features": {
                "keywords": [
                    "药品禁用",
                    "招采违规",
                    "裁员潮",
                    "集采中标"
                ],
                "sentiment_score": -0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "17个药品被禁用，招采违规遭严打，知名药企掀裁员潮，科伦、齐鲁...27个注射剂集采中标 其他违规处罚",
                "Correlation": 5,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-06-19",
            "original_text": "迷茫期的一张投资明牌",
            "features": {
                "keywords": [
                    "投资明牌",
                    "迷茫期"
                ],
                "sentiment_score": 0.3,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "迷茫期的一张投资明牌",
                "Correlation": 4,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-06-19",
            "original_text": "百时美施贵宝31亿美元合作开发，这款ADC有何独特之处？",
            "features": {
                "keywords": [
                    "百时美施贵宝",
                    "ADC",
                    "合作开发"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "百时美施贵宝31亿美元合作开发，这款ADC有何独特之处？",
                "Correlation": 6,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-06-19",
            "original_text": "速递 | 23亿美元助力开发即用型自然杀伤细胞疗法，Kite公司达成合作",
            "features": {
                "keywords": [
                    "自然杀伤细胞疗法",
                    "Kite公司",
                    "合作"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "速递 | 23亿美元助力开发即用型自然杀伤细胞疗法，Kite公司达成合作",
                "Correlation": 6,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-06-19",
            "original_text": "前沿 | 克服PARP抑制剂耐药性，“老”抗生素展现“新”抗癌潜力",
            "features": {
                "keywords": [
                    "PARP抑制剂",
                    "抗生素",
                    "抗癌潜力"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "前沿 | 克服PARP抑制剂耐药性，“老”抗生素展现“新”抗癌潜力",
                "Correlation": 5,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]